36 results about "Drug withdrawal symptoms" patented technology

Compositions useful for treating an individual with nicotine dependence comprising a combination of an α3β4 nicotinic receptor antagonist and a nicotine metabolite are disclosed. More particularly, compositions comprising cotinine or a pharmaceutically acceptable salt thereof are disclosed. Methods of alleviating nicotine withdrawal symptoms and / or tobacco usage by administration of these compositions are also disclosed.

The invention includes a patch and method for transdermal delivery of bupropion base. In the method of this invention, a patient is administered a bupropion base in an amount effective to alleviate withdrawal symptoms and to prevent or reduce craving of nicotine in said patient. Alternatively, an effective amount of bupropion base is delivered to alleviate depression in a patient or to treat obesity. A transdermal patch includes a bupropion base. The bupropion base can be mixed with an acceptable pharmaceutical carrier.

This invention provides methods and pharmaceutical compositions for preventing or treating physical dependence and / or withdrawal associated with narcotic use, in particular by modulating a 5-HT3 receptor. Using a computational genetic approach in mice, a gene conserved between mice and humans was identified as candidate as a modulator of physical dependence to morphine. Administration of compounds that modulate 5-HT3 receptors was found to control withdrawal from morphine in mice and humans.

Compositions for reducing dependency and addiction to substances of abuse are provided. Chloride channels such as the GABAA receptors are altered under conditions of dependency and withdrawal such that the electrophysiological properties of the GABAA receptor containing neurons are altered thereby providing a pathophysiological condition resulting in symptoms of dependency and withdrawal such as anxiety. Specifically, under conditions of withdrawal the relative ratio of the a1 receptor subunit decreases relative to the a4 receptor subunit. Endogenous neurosteroid production is also associated with the molecular changes underlying the alterations of GABA-gated chloride channels. Compositions of at least two compounds including at least one inhibitor of neurosteroid production are useful for treating the pathophysiology of addiction, dependency and substance abuse withdrawal.

The invention is suitable for the technical field of traditional Chinese medicines, provides application of free sulfur in preparing drug treatment and rehabilitation medicaments and also provides a drug treatment and rehabilitation Chinese herbal composition of which crude drugs include a sulfur element and at least one Chinese herbal component, wherein the weight percentage of the sulfur element to the Chinese herbal component is (0.1-99):(99-0.1); the sulfur element is the free sulfur, sublimed sulfur, precipitated sulfur, sulphion or a sulfocompound. The free sulfur is applied to the preparation of the drug treatment and rehabilitation medicaments, can block the euphoria brought by drugs and can bring a long-efficient and secondary taking prevention effect. A Chinese herbal preparation prepared from the Chinese herbal composition provided by the invention has favorable curative effect for opioid drugs, excitotoxicity drugs and various controlled substances and has stronger inhibitory action for heroin dependent patients longing for the drugs, a certain inhibitory action in the euphoria generated by opioid substances, better curative effect for protracted withdrawal syndrome and action in promoting the restoring of physiological functions of organisms.

A multi-component compound for the simultaneous treatment of nicotine addiction and the side effects of nicotine withdrawal, such as excessive appetite. The first component is a bivalent negative sulfur compound in an amount effective to control nicotine craving or the withdrawal symptoms resulting from nicotine withdrawal. The bivalent negative sulfur is selected from a group that includes, but is not limited to, alkyl sulfides, colloidal sulfur, hydropersulfides, organic thio compounds or their salts. The second component is a serotonin precursor, such as tryptophan or its derivative 5-HTP, which is used to assist the body in producing more serotonin which in turn suppresses appetite. The appetite suppressant(s) are combined with the bivalent negative sulfur compound(s) to provide a single compound that reduces nicotine craving and simultaneously suppresses increased appetite resulting from nicotine withdrawal. The compound alters the perceived taste of tobacco smoke such that it is no longer enjoyable.

This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of 50 ng / mL to 180 ng / mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.

The invention discloses a medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances. The medicament is prepared from the following components by weight percent: 2-95% of antipsychotics, 0.001-5% of alpha2 adrenergic agonists, 0-5% of anticholinergic agent, 0-80% of nonopioid analgesic, and 0-10% of benzodiazepine. The pharmaceutical composition disclosed by the invention achieves an ideal effect when the symptoms of a sufferer abusing stimulants such as benzedrine, or abusing the opiates substances in a merging manner are treated; the withdrawal symptom can be rapidly and obviously controlled; the detoxification recovery rate can be up to over 90%.

The invention discloses application of cytotoxin (CTX1) from snake venom to preparation of a medicament for rehabilitating. Proved by the experiment, the CTX1 can better eliminate the behavioral sensitization of addict rats by morphine, eliminate the medicament thirst behavior and the abstinence syndrome of rats and has favorable rehabilitating effect. In addition, the invention can improve the function state, the diet and the activities of the addict rats and remarkably increase the weight, thereby recovering normal physiological activity.

The present invention relates to the treatment of withdrawal and craving symptoms as an aid in smoking cessation by administration of one or more dosages of a medication containing Passiflora incarnata.

The present invention encompasses methods of treating patients for tobacco addiction and nicotine addiction, for palliating the effects of nicotine withdrawal, for providing or facilitating the effects of smoking cessation therapies and as long-term smoking cessation maintenance therapy. The invention also includes related pharmaceutical compositions comprising nicotine receptor antagonists and either an anti-depressant or an anti-anxiety drug. Specific combinations of drugs (mecamylamine HCl and bupropion HCl) as well as mecamylamine in combination with certain drug classes (e.g., anti-anxiety drugs and anti-depressants) comprise the pharmaceutical compositions disclosed. These compositions are also contemplated for use in the treatment of cocaine addiction and the treatment of alcohol dependence.

The invention relates to a drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome, which comprises the following components in percent by weight: 2-95 percent of antipsychotics, 0.001-5 percent of a2 adrenergic receptor agonist, 0-5 percent of anticholinergic drug, 0-80 percent of non-opiates pain easing agent and 0-10 percent of benzodiazepines drugs. When used for treating symptoms occurring in patients abusing exhilarants of Benzedrine and the like or integrally abusing opioid, the drug achieves better effect, can rapidly and remarkably control abstinence syndrome, and has detoxification cure rate reaching over 90 percent.

An acid-modified arabinogalactan protein composition, having an arabinose-galactose ratio of less than 3.5:1 or less than 80% of the arabinose:galactose ratio of the arabinogalactan protein component of the composition prior to acid modification, prepared from Astragalus membranaceus, especially from the roots of Atragalus membranaceus, is capable of reconstitution into an aqueous intravenously injectable formulation; and is useful for stimulating hematopoiesis, inducing the proliferation or maturation of megakaryocytes, stimulating the production of IL-1beta, Il-6, TNF-alpha, IFN-gamma, GM-CSF, or G-CSF, stimulating the production or action of neutrophils, treating neutropenia, anemia, or thrombocytopenia, accelerating recovery from exposure (e.g. accidental or non-therapeutic exposure, as well as therapeutic exposure) to cytotoxic agents or radiation, treating cachexia, emesis, or drug withdrawal symptoms, or modifying biological responses or protecting hepatic cells in hepatitis B, in a mammal when intravenously administered to the mammal.

Disclosed are an extract that is effective in treating drug addiction and a preparation method therefor. An effective component of the extract has the following chemical structural characteristics: a cholestenol compound with hydroxyl (OH) at position 3 and a double bond between position 5 and position 6, or a cholestenol compound with hydroxyl (OH) at position 3, a double bond between position 5 and position 6 and a double bond between position 22 and position 23. The extract can be extracted from the traditional Chinese medicine Agriolima agrestis. The extract of the present invention is safe in acute toxicity, sedative and hypnotic without physical and psychic dependence, has an inhibitory effect on excitability in mouse caused by morphine and benzedrine and a detoxification treatment effect on the withdrawal symptoms in morphine-dependent rats, and is useful in the development of medications or food for treating drug addiction.

The disclosure relates to a method of treating or preventing a condition in a subject associated with the activation of an opioid receptor in the periphery by administering an effective amount of 5-(2-methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide (Compound I). In particular, the disclosure relates to a method of treating or preventing opioid- induced constipation or opioid-induced bowel dysfunction in a human without reducing centrally-mediated opioid analgesia or producing central opioid withdrawal symptoms by administering an effective amount of Compound (I). The disclosure further relates to the use of Compound (I) for the preparation of a medicament for the treatment or prevention of a condition in a subject associated with the activation of an opioid receptor in the periphery.

The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABAA chloride channel activity to treat alcohol and / or stimulant substance abuse. The present invention also relates to methods of, and protocols for, relieving symptoms associated with alcohol and / or stimulant substance abuse in a comprehensive treatment plan. More specifically, the present invention relates to the use of a selective chloride channel modulator, such as flumazenil, to treat alcohol and / or psychostimulant dependency, the withdrawal symptoms associated therewith, and the cravings associated therewith.

The invention relates to a product for preventing a relapse after drug rehabilitation. When a raw material of the product for preventing the relapse after drug rehabilitation are prepared, tetrahydropalmatine of active ingredients is made into fine powder being 100 mesh or above in a light resistant place at low temperature; under the light resistant condition, the fine powder is added in an acidic water-soluble solvent to obtain suspension liquid, and the raw material of the product for preventing the relapse after drug rehabilitation is obtained, wherein the acidic water-soluble solvent is amixture of diethyl ether, trichloromethane and at least one alcohol of C2-C5 alcohol, and acid is sulfuric acid or hydrochloric acid. Accordingly, when the raw material is prepared, diethyl ether andtrichloromethane are added in the solvent, tetrahydropalmatine can be well dissolved, and then the prevention effect of the product for preventing the relapse after drug rehabilitation is improved, the prepared product can relieve morphine and related drug withdrawal symptoms and inhibit heart addiction on drugs, no toxicity exists, addiction does not occur, drug dependence is not formed, and convenience is brought to use.

Non-pharmaceuticals method of treating the effects of addiction withdrawal are described. The method includes providing a person with stimuli include visual and / or auditory stimuli which are pulsed at the rate of various types of brain waves. The use of the method lessens various withdrawal symptoms, such as anxiety, sleepiness, sweating, tearing of the eyes, running of the nose, goosebumps, shaking, hot flushes, cold flushes, bones aching, muscles aching, restlessness, nausea, vomiting, muscle twitching, stomach cramps, pain, the need to use an opioid, the desire to use an opioid, sleep disturbances. and the use of rescue medications.

The invention relates to an intravenous drip prescription for blocking the poisoning path of heroin or morphine drug and application thereof. The intravenous drip prescription comprises cerebrolysin, nootropil, cimetidine, scopolamine butylbromide, nefopam, vitamin B complex, vitamin B1, vitamin C, ketorolac, guronsan, buscopan, sukerin and other components. The prescription reaches blocking of drug poisoning by activating the liver and in vivo circulation system of patients. According to drug blocking application, at the acute withdrawal part, the intravenous drip prescription is employed for injection, also the drug delivery time and a safe medication dosage are controlled according to clinical symptoms, and an appropriate amount of haloperidol and other assistant agents are added, and through the procedures of detoxification, symptom relieving, restlessness inhibiting and sobering, etc., acute withdrawal syndromes of acute withdrawal drug addicts can be quickly and successfully blocked.

A method of detoxifying a patient addicted to at least one drug comprises the step of administering a first-medication component to the patient for mitigating drug withdrawal symptoms of the patient. The method further comprises the step of administering an anesthetic component to the patient for putting the patient in a sedated state. The method further comprises the step of administering a detoxification component to the patient for detoxifying the patient of the drug(s) while the patient is in the sedated state. The detoxification component can comprise naloxone. The method further comprises the step of administering a second-medication component to the patient for further mitigating drug withdrawal symptoms of the patient while the patient is in the sedated state. The second-medication component can comprise naltrexone. The method further comprises the step of terminating administration of the anesthetic component to the patient for reviving the patient from the sedated state.

The invention relates to the application of baclofen in the opium drug abstinence treatment and belongs to the technical field of addiction medicine application. According to the characteristic of baclofen GABA beta-receptor stimulant, the invention applies the baclofen with the daily dosage of 15 to 120mg as the drug for the opium drug abstinence treatment by virtue of the mutual reaction relation between the baclofen GABA beta-receptor stimulant and an opium system, the close relation between a GABA beta-receptor and the opium drug acute abstinence, the advantages of the GABA beta-receptor stimulant reducing the exacting action of the opium drug, etc. The baclofen is concretely applied in the comprehensive treatments, such as opium drug detoxification (acute abstinence symptom), healing (protracted abstinence syndrome and overcoming psychological dependence), etc. The clinical trial shows that the invention not only develops the application range of traditional drugs, but also has the advantages of investment saving, the low cost of product, strong practicability, good effect, etc. The baclofen can be widely applied to the opium drug abstinence detoxification and healing treatment.

A substance with sedative effect comprises a therapeutically effective amount of a gamma-pyrone such as comenic acid, meconic acid, chelidonic acid, and alike in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 5 and 200 mg of active ingredient per kilogram of a body weight of a patient, the substance can be used to treat various neurotic disorders such as insomnia, anxiety, neurosis, depression as well as withdrawal symptoms for drug addiction patients, especially for patients addicted to opioid-based drugs. The substance can be delivered in a number of ways of systemic administration of a pharmaceutical agent including oral, parenteral, transdermal, and transmucosal administration. For drug addicted patients, the preferred method of administration involves a subcutaneous implant providing a continuous release of an active ingredient at an effective daily rate over the entire treatment period ranging from 5 to 30 days, and preferably from 13 to 20 days.

The present invention relates to the treatment of withdrawal and craving symptoms as an aid in smoking cessation by administration of one or more dosages of a medication containing Passiflora incarnata.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to a drug for treating menstrual irregularity with protracted withdrawal symptoms. The drug comprises, by mass, 9-12g of bupleurum, 9-12g of cassia twig, 4-6g of dried ginger, 10-12g of trichosanthes kirilowii maxim, 6-9g of scutellaria baicalensis, 10-12g of oyster, 12-15g of prepared rehmannia root, 10-12g of ligusticum wallichii, 12-15g of fried angelica, 12-15g of radix paeoniae alba and 5-6g of honey-fried licorice root. A drug formula has the effects of strengthening the middle warmer, nourishingyin without greasiness, warming without dryness, achieving harmony between yin and yang, can effectively improve the endometrial thickness and the gonadal hormone concentration of a methamphetamine dependent patient, and achieves a significant treatment effect on the menstrual irregularity with protracted withdrawal symptoms and amenorrhea.

A drug-dropping medicine for opiomania is prepared from 12 Chinese-medicinal materials including eel, corydalis tuber, ginseng, dandelion herb, etc. Its advantages are high curative effect, quickly taking its effect (30 min) and short course of treatment (4-7 days).

The invention relates to the application of paralest in the opium drug detoxification abstinence treatment and belongs to the technical field of addiction medicine application. According to the functional characteristics of paralest of selectively breaking the cholinergic nerve tract of striaturn, inhibiting the hyperfunction of acetylcholine, correspondingly improving the effect of brain dopamine, being good for keeping or recovering the balance of two transmitter systems of striaturn dopamine (DA) and acetylcholine (Ach) and causing no drug dependence after long time usage, the paralest is used for the treatments, such as opium drug detoxification (acute abstinence symptom), healing (protracted abstinence syndrome), etc. Experimentation on animals and clinical trial show that the invention not only develops the application range of traditional drugs, but also has the advantages of investment saving, the low cost of product, strong practicability, good effect, etc. The paralest can be widely applied to the opium drug abstinence treatment.

The present invention provides a method for preventing or treating opiate tolerance and dependence by administering to an individual in need of such treatment with a pharmaceutically effective amount of a blocking reagent for ephrinB-EphB signaling. The opiate tolerance and dependence can be caused by chronic morphine treatment and withdrawal. The blocking reagent can be an EphB receptor blocker such as EphB1-Fc and EphB2-Fc.

The disclosure relates to a method of treating or preventing a condition in a subject associated with the activation of an opioid receptor in the periphery by administering an effective amount of 5-(2-methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide (Compound I). In particular, the disclosure relates to a method of treating or preventing opioid-induced constipation or opioid-induced bowel dysfunction in a human without reducing centrally-mediated opioid analgesia or producing central opioid withdrawal symptoms by administering an effective amount of Compound I. The disclosure further relates to the use of Compound I for the preparation of a medicament for the treatment or prevention of a condition in a subject associated with the activation of an opioid receptor in the periphery.